Bitte beachten Sie: Suchbegriffe unter einer Länge von 3 Buchstaben werden ignoriert.
267 Treffer:
21.
A Phase 2, Randomized, Double-Blind, Placebo- and Active-Comparator- Controlled Clinical Study of V940 (mRNA-4157) Plus Pembrolizumab Versus Placebo Plus Pembrolizumab in Participants With First-Line Advanced Melanoma (INTerpath-012)
NCT Heidelberg » Für Ärzte » Studien » Hauttumoren » Melanom
Datum: 2026-04-04
22.
Randomized, Ph3 Clinical Study Comparing Vusolimogene Oderparepvec in Combination With Nivolumab Vs Treatment of Physician's Choice in Patients With Advanced Melanoma That Progressed on Anti-PD-1 and Anti-CTLA-4 Containing Treatment.
NCT Heidelberg » Für Ärzte » Studien » Hauttumoren » Melanom
Datum: 2026-04-04
23.
An Open Label Phase II Randomized Trial of BNT113 in Combination With Pembrolizumab Versus Pembrolizumab Monotherapy as a First Line Therapy in Patients With Unresectable Recurrent, or Metastatic Head and Neck Squamous Cell Carcinoma (HNSCC) Which is Posi
NCT Heidelberg » Für Ärzte » Studien » Kopf-/Hals Tumoren
Datum: 2026-04-04
24.
Phase I Open-label, Dose Escalation Trial of BI 1831169 Monotherapy and in Combination With an Anti-PD-1 mAb in Patients With Advanced or Metastatic Solid Tumors
NCT Heidelberg » Für Ärzte » Studien » Hauttumoren » Melanom
Datum: 2026-04-04
25.
A prospective, observational, multicenter clinical performance study to evaluate IOpener®-melanoma test for predicting response to combination or mono immunotherapy in stage III or IV cutaneous melanoma patients
NCT Heidelberg » Für Ärzte » Studien » Hauttumoren » Melanom
Datum: 2026-04-04
26.
Phase 2/3 Randomized Study of Tebentafusp as Monotherapy and in Combination With Pembrolizumab Versus Investigator's Choice in HLA-A*02:01-positive Participants With Previously Treated Advanced Melanoma (TEBE-AM)
NCT Heidelberg » Für Ärzte » Studien » Hauttumoren » Melanom
Datum: 2026-04-04
27.
A Modular Phase I/II, Open-label, Multi-Centre Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Preliminary Efficacy of AZD3632 Monotherapy or in Combination With Anticancer Agents in Participants with Advanced Haematolo
NCT Heidelberg » Für Ärzte » Studien » Hämatologische Neoplasien » Myelodysplastisches Syndrom (MDS)
Datum: 2026-04-04
28.
A Phase 3, Open-Label, Randomized Study of BGB-16673 Compared to Investigator's Choice (Idelalisib Plus Rituximab or Bendamustine Plus Rituximab or Venetoclax Plus Rituximab Retreatment) in Patients With Chronic Lymphocytic Leukemia or Small Lymphocytic L
NCT Heidelberg » Für Ärzte » Studien » Hämatologische Neoplasien » Non-Hodgkin-Lymphome (incl. CLL)
Datum: 2026-04-04
29.
A pivotal Phase II randomised, multi-centre, open-label study to evaluate the efficacy and safety of MB-CART2019.1 compared to standard of care therapy in participants with relapsed/refractory diffuse large B-cell lymphoma (R-R DLBCL), who are not eligibl
NCT Heidelberg » Für Ärzte » Studien » Hämatologische Neoplasien » Non-Hodgkin-Lymphome (incl. CLL)
Datum: 2026-04-04
30.
Combining Loncastuximab Tesirine and Epcoritamab in Relapsed/Refractory Diffuse Large B-cell Lymphoma (DLBCL)Combining Loncastuximab Tesirine and Epcoritamab in Relapsed/Refractory Diffuse Large B-cell Lymphoma (DLBCL)
NCT Heidelberg » Für Ärzte » Studien » Hämatologische Neoplasien » Non-Hodgkin-Lymphome (incl. CLL)
Datum: 2026-04-04